drugset / Trial / NCT01185873
A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment
NaSingle-groupOpen-labelTreatment
Summary
This non-randomized, multi-center, open-label study will evaluate the pharmacokinetics and the safety and tolerability of danoprevir (RO5190591) and ritonavir in healthy volunteers and patients with mild, moderate or severe hepatic impairment. Participants will be administered repeated daily doses of danoprevir and ritonavir. The anticipated time on study treatment is 10 days.
Timeline
- Start
- 2011-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritonavir | Other / unclassified | — | Oral |
| Subject | danoprevir | Small molecule | — | Oral |
Indications
No indication recorded.